Navigation Links
Generic Pharma Partnering Yearbook 2013 - Access to the Partnering Deals and Agreements Globally
Date:1/31/2013

omprehensive directory of all partnering deals announced during 2012. 
The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.

Key benefits

Generic Pharma Partnering Yearbook 2013 series provides the reader with the following key benefits:

  • In-depth understanding of recent dealmaking trends during 2012
  • Comprehensive access to all deals entered into by the world's biopharma companies during 2012
  • Detailed access to actual partnership deals and contracts entered into by the leading fifty bigpharma companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Generic Pharma Partnering Yearbook 2013 series is intended to provide the reader with an in-depth understanding and access to parthering and M&A trends and structure of deals entered into by leading companies worldwide.

Generic Pharma Partnering Yearbook 2013 includes:

  • Trends in dealmaking in the biopharma industry during 2012
  • Comprehensive directory of
    '/>"/>

SOURCE Bharat Book Bureau
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Watsons Generic Yaz(R) Receives FDA Approval
2. Watsons Generic BONIVA® 150mg Receives FDA Approval
3. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
4. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
5. Lupin Receives FDA Approval for Generic LYRICA(R)
6. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Pharmasset Reports Fiscal Year End 2011 Financial Results
11. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. (NASDAQ: ... is striving to become a leader in the development ... announced that the final CVac data from the Phase ... clear trend for a clinically meaningful improvement in Overall ... remission patients. In the group of second ...
(Date:5/21/2015)... 2015  The EveryLife Foundation for Rare Diseases ... Amy Klobuchar (D-MN) today for introducing ... Treatments, or OPEN ACT. Supported by ... this bipartisan legislation promises to rapidly bring hundreds ... disease patients by incentivizing drug makers to "repurpose" ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... $2.0 Million -, MONTVALE, N.J., Aug. 26 ... it has secured,$2.0 million through the sale of approximately ... under its June 2007 equity financing agreement,with an investment ... Pharmaceuticals exercised its option to complete the third,and final ...
... to empower purification of stem ... cells and their differentiated progeny, ... and the Burnham Institute for Medical Research,("Burnham") today announced ... applications on Cyntellect,s in situ live cell imaging and,laser ...
... The 2008 European Gene,Expression Targeting Platform ... Biogenics Ltd. for developing the Vascular Targeting,System ... advancements,in gene expression-based treatments where angiogenesis is ... a potent and flexible technology permitting,the limitation ...
Cached Biology Technology:Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 2Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 3Cyntellect to Collaborate With the Burnham Institute for Medical Research 2Cyntellect to Collaborate With the Burnham Institute for Medical Research 3Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 2Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 3
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Los Angeles, London, New Delhi, Singapore and Washington DC ... to be advertised directly to the patient, and the results ... as the future adoption of pharmacogenetic/genomic testing, according to a ... to be published in the August 2009 issue of the ...
... - In the July issue of Biomaterials , ... Florida (UCF) report on the first lab-grown motor nerves ... in the human body. The model system will ... such as diabetic neuropathy and later, possibly multiple sclerosis ...
... (BOSTON) July 21, 2009 - A menace to ... the World Organisation for Animal Health (OIE) has declared ... cattle-killing disease that threatened its food supply and its ... July 25, 2009. A team from Tufts University,s ...
Cached Biology News:Genetic tests advertised directly to the consumer 2Researchers design first model motor nerve system that's insulated and organized like the human body 2Ethiopian government celebrates rinderpest eradication 2Ethiopian government celebrates rinderpest eradication 3
... Polynucleotide Kinase catalyzes the transfer ... to the 5-terminus of polynucleotides ... 5-hydroxyl group. The enzyme, purified ... be used to phosphorylate RNA, ...
... Thermo Labsystems Nepheloskan Ascent ... adapted to measurement in microplates. ... offers an ultra-sensitive technique for ... ideal for solubility testing in ...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
Biology Products: